Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient …
AW Armstrong, SA Foster, BS Comer, CY Lin… - BMC dermatology, 2018 - Springer
Background Little is known regarding real-world health outcomes data among US psoriasis
patients, but electronic health records (EHR) that collect structured data at point-of-care may …
patients, but electronic health records (EHR) that collect structured data at point-of-care may …
Treatment patterns, adherence, and persistence among psoriasis patients treated with biologics in a real-world setting, overall and by disease severity
MJ Murage, A Anderson, D Casso… - Journal of …, 2019 - Taylor & Francis
Purpose: Describe treatment patterns by disease severity among biologic-treated psoriasis
patients. Materials and methods: We selected our study cohort in the IQVIA PharMetrics Plus …
patients. Materials and methods: We selected our study cohort in the IQVIA PharMetrics Plus …
Real-world treatment patterns and healthcare costs in patients with psoriasis taking systemic oral or biologic therapies
S Thai, J Zhuo, Y Zhong, Q Xia, X Chen… - Journal of …, 2023 - Taylor & Francis
Background Psoriasis is a chronic, immune-mediated, systemic inflammatory disorder
associated with high costs. This study evaluated real-world treatment patterns and …
associated with high costs. This study evaluated real-world treatment patterns and …
Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population
JA Doshi, J Takeshita, L Pinto, P Li, X Yu, P Rao… - Journal of the American …, 2016 - Elsevier
Background Studies indicate adherence to biologics among patients with psoriasis is low,
yet little is known about their use in the Medicare population. Objective We sought to …
yet little is known about their use in the Medicare population. Objective We sought to …
Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis
BACKGROUND: Despite widespread dissatisfaction and low treatment persistence in
moderate to severe psoriasis, patients' reasons behind treatment discontinuation remain …
moderate to severe psoriasis, patients' reasons behind treatment discontinuation remain …
Health care utilization and cost associated with biologic treatment patterns among patients with moderate to severe psoriasis: analyses from a large US claims …
SR Feldman, H Tian, X Wang, R Germino - Journal of Managed Care & …, 2019 - jmcp.org
BACKGROUND: Discontinuation or switching of biologic treatment among patients with
psoriasis imposes a great economic burden. OBJECTIVE: To assess the health care …
psoriasis imposes a great economic burden. OBJECTIVE: To assess the health care …
Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National …
AW Armstrong, AD Robertson, J Wu, C Schupp… - JAMA …, 2013 - jamanetwork.com
Importance Psoriasis and psoriatic arthritis inflict significant morbidity. Data on
undertreatment, treatment use, and treatment satisfaction are paramount to identify priority …
undertreatment, treatment use, and treatment satisfaction are paramount to identify priority …
Treatment patterns, healthcare resource utilization, and costs in patients with moderate‐to‐severe psoriasis treated with systemic therapy in Japan: A retrospective …
Y Tada, H Kim, D Spanopoulos… - The Journal of …, 2022 - Wiley Online Library
The real‐world treatment landscape for patients with moderate‐to‐severe psoriasis
receiving systemic therapies in Japan is not well understood. This study describes the …
receiving systemic therapies in Japan is not well understood. This study describes the …
Satisfaction and awareness of systemic psoriasis treatments: a national survey comparing biologic and nonbiologic users
A Ighani, AM Yu, VK Sandhu… - Journal of …, 2019 - journals.sagepub.com
Background: There is ongoing development of new therapies for psoriasis, including
biologic and systemic agents such as interleukin-17, interleukin-23, and phosphodiesterase …
biologic and systemic agents such as interleukin-17, interleukin-23, and phosphodiesterase …
Patient-reported treatment satisfaction and choice of dosing frequency with biologic treatment for moderate to severe plaque psoriasis
M Zhang, SK Brenneman, CT Carter… - Patient preference …, 2015 - Taylor & Francis
Background Moderate to severe plaque psoriasis has a serious effect on health-related
quality of life. Patients treated with biologic medications place importance on satisfaction …
quality of life. Patients treated with biologic medications place importance on satisfaction …